TNIK Blocking Peptide for STJ503344 is synthetically produced from the 1250-1300 sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Sythetic peptide taken within amino acid region 1250-1300 on human TRAF2 and NCK-interacting protein kinase protein.
Immunogen Region
1250-1300
Specificity
This blocking peptide is recommended for use in combination with TNIK antibody, STJ503344
Additional Info
Tissue Specificity
Expressed ubiquitously. Highest levels observed in heart, brain and skeletal muscle. Expressed in normal colonic epithelia and colorectal cancer tissues.
Post Translational Modifications
Autophosphorylated. Autophosphorylation is activated by RAP2A and induces association to the cytoskeletal fraction.
Function
Serine/threonine kinase that acts as an essential activator of the Wnt signaling pathway. Recruited to promoters of Wnt target genes and required to activate their expression. May act by phosphorylating TCF4/TCF7L2. Appears to act upstream of the JUN N-terminal pathway. May play a role in the response to environmental stress. Part of a signaling complex composed of NEDD4, RAP2A and TNIK which regulates neuronal dendrite extension and arborization during development. More generally, it may play a role in cytoskeletal rearrangements and regulate cell spreading. Phosphorylates SMAD1 on Thr-322. Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway.
